---
title: "Sinocelltech Group Limited (688520.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688520.SH.md"
symbol: "688520.SH"
name: "Sinocelltech Group Limited"
industry: "Biotechnology"
datetime: "2026-05-21T07:39:08.761Z"
locales:
  - [en](https://longbridge.com/en/quote/688520.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688520.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688520.SH.md)
---

# Sinocelltech Group Limited (688520.SH)

## Company Overview

Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers. It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and other autoimmune diseases; SCTC21C for the treatment of CD38-positive blood cancers; SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma; SCTB14 for immunotherapy of multiple solid tumors; SCTB41 for multiple solid tumor immunotherapy; SCTV02 to prevent respiratory diseases; SCTV04C to prevent herpes zoster; SCT520FF, an anti-angiogenic biopharmaceutical product; and SCTT11 for the treatment of thyroid eye disease. The company was founded in 2007 and is based in Beijing, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.sinocelltech.com](https://www.sinocelltech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: D (0.76)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 67 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -43.65% |  |
| Net Profit YoY | -892.25% |  |
| P/B Ratio | 274.54 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 19406299896.68 |  |
| Revenue | 1360985775.08 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -152.92% | E |
| Profit Margin | -58.98% | E |
| Gross Margin | 89.57% | A |
| Revenue YoY | -43.65% | E |
| Net Profit YoY | -892.25% | E |
| Total Assets YoY | 31.44% | A |
| Net Assets YoY | 320.27% | A |
| Cash Flow Margin | 32.52% | D |
| OCF YoY | -43.65% | E |
| Turnover | 0.34 | D |
| Gearing Ratio | 81.60% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sinocelltech Group Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-43.65%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-892.25%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "274.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "19406299896.68",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1360985775.08",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-152.92%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-58.98%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "89.57%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-43.65%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-892.25%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "31.44%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "320.27%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "32.52%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-43.65%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.34",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "81.60%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -24.17 | 60/81 | 328.12 | 290.83 | 199.59 |
| PB | 274.54 | 83/81 | 278.99 | 273.47 | 115.28 |
| PS (TTM) | 14.26 | 61/81 | 12.75 | 11.10 | 9.44 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-02T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 41.88 |
| Highest Target | 55.00 |
| Lowest Target | 55.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688520.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688520.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688520.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**